Fundraising Fox
iOncologi
Gainsville, US · Delaware corporation · 4 employees on LinkedIn
Find your way into iOncologi
Sign up to see every warm intro you have to iOncologi
- Paths you didn't know you had: your email and LinkedIn already hold routes to the iOncologi team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
iOncologi develops immunotherapy platforms designed to treat cancer by priming the immune system to attack tumors and overcoming immune resistance. The company's proprietary technologies target solid tumors and refractory cancers through personalized immune conditioning and cell-based approaches.
Founders & leadership
DE
Dr. Edgardo Rodriguez-LebronCo-founder, President, and CEO
DD
Dr. Duane MitchellCo-founder and Chairman
DC
Dr. Catherine FloresCo-founder
ER
Edgardo RodriguezExecutive
MM
Michelle MitchellExecutive
Board
PK
Peter KashBoard director
Reported raises · per SEC filings
Form D private placements$3.3M disclosed across 2 rounds · 2025
▶$250KraisedMay 2025 · 3 investors · BiotechnologyRule 506(b)
▶$250KraisedMay 2025 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paolo FundaroDirector
- Peter KashDirector
- Duane MitchellDirector
- Mona FloresDirector
- Edgardo Rodriguez-LebronExecutive Officer, Director
- Offering amount
- $12M
- Amount sold
- $250K
- First sale
- May 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedMar 2025 · 17 investors · BiotechnologyRule 506(b)
▶$3MraisedMar 2025 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Edgardo RodriguezExecutive Officer, Director
- Michelle MitchellExecutive Officer, Director
- Peter KashDirector
- Catherine FloresDirector
- Duane MitchellExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $3M
- Sales commissions
- $142.7K
- Placement agents
- ARCADIA SECURITIES, LLC (Brookline Capital Markets)
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 6
ImmuneeringImmuneering develops Deep Cyclic Inhibitors, a class of oncology medicines designed to pulse dosing faster than cancer's adaptive mechanisms to limit resistance and reduce side effects. The company targets more durable tumor control and improved tolerability for cancer patients.
EvolveImmune TherapeuticsEvolveImmune develops immunotherapy treatments for cancer patients. The company focuses on discovering and developing novel biotherapeutics in immuno-oncology and related immune-mediated diseases.
InimmuneInimmune is a clinical-stage biotech company developing immunotherapies for allergy, cancer, infectious, and autoimmune diseases. The company combines immunology and vaccine expertise to advance its clinical and pre-clinical pipeline.
Immune-Onc TherapeuticsImmune Onc is a biotechnology company developing medicines to treat patients with hard-to-treat cancers and autoimmune diseases, with expertise in translational medicine and clinical development.
ImmunocoreImmunocore is a biotechnology company developing T cell receptor (TCR) based immunomodulating therapies for patients with cancer, infectious diseases, and autoimmune diseases.
OncimmuneOncimmune is a biomarker discovery and diagnostics company specializing in proteomics and bioinformatics technologies for autoimmunity, cancer research, and clinical drug development. The company serves pharmaceutical, biotech, and academic partners by developing diagnostic tools and biomarkers for various phases of clinical development.
Companies working in the same space as iOncologi.
Frequently asked questions
- What does iOncologi do?
- iOncologi develops immunotherapy platforms designed to treat cancer by priming the immune system to attack tumors and overcoming immune resistance. The company's proprietary technologies target solid tumors and refractory cancers through personalized immune conditioning and cell-based approaches.
- Who founded iOncologi?
- iOncologi was founded by Dr. Edgardo Rodriguez-Lebron, Dr. Duane Mitchell, Dr. Catherine Flores.
- How much funding has iOncologi raised?
- iOncologi has disclosed $3.3M raised across 2 rounds.
- Where is iOncologi headquartered?
- iOncologi is headquartered in Gainsville, US.